These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
483 related articles for article (PubMed ID: 24113428)
1. Regulation of advanced therapy medicinal products in Europe and the role of academia. Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428 [TBL] [Abstract][Full Text] [Related]
2. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215 [TBL] [Abstract][Full Text] [Related]
3. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation. de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764 [TBL] [Abstract][Full Text] [Related]
4. Creating conditions for the success of the French industrial advanced therapy sector. Lirsac PN; Blin O; Magalon J; ; Angot P; de Barbeyrac E; Bilbault P; Bourg E; Damour O; Faure P; Ferry N; Garbil B; Larghero J; Nguon M; Pattou F; Thumelin S; Yates F Therapie; 2015; 70(1):69-94. PubMed ID: 25747840 [TBL] [Abstract][Full Text] [Related]
5. Encountering Challenges with the EU Regulation on Advance Therapy Medical Products. Mansnérus J Eur J Health Law; 2015 Dec; 22(5):426-61. PubMed ID: 26665690 [TBL] [Abstract][Full Text] [Related]
6. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries. Coppens DGM; Hoekman J; De Bruin ML; Slaper-Cortenbach ICM; Leufkens HGM; Meij P; Gardarsdottir H Cytotherapy; 2020 Oct; 22(10):592-600. PubMed ID: 32563611 [TBL] [Abstract][Full Text] [Related]
7. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products]. Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546 [TBL] [Abstract][Full Text] [Related]
8. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Abou-El-Enein M; Römhild A; Kaiser D; Beier C; Bauer G; Volk HD; Reinke P Cytotherapy; 2013 Mar; 15(3):362-83. PubMed ID: 23579061 [TBL] [Abstract][Full Text] [Related]
9. The Current State of Advanced Therapy Medicinal Products in the Czech Republic. Kočí Z; Boráň T; Krůpa P; Kubinová Š Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533 [TBL] [Abstract][Full Text] [Related]
10. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany. Renner M; Anliker B; Sanzenbacher R; Schuele S Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214 [TBL] [Abstract][Full Text] [Related]
11. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union. Beattie S; Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251 [TBL] [Abstract][Full Text] [Related]
12. Regulatory structures for gene therapy medicinal products in the European Union. Klug B; Celis P; Carr M; Reinhardt J Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782 [TBL] [Abstract][Full Text] [Related]
13. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Iglesias-Lopez C; Obach M; Vallano A; Agustí A Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292 [TBL] [Abstract][Full Text] [Related]
14. Exploring Solutions to Foster ATMP Development and Access to Patients in Europe. Salvatore V Eur J Health Law; 2020 May; 27(3):259-273. PubMed ID: 33652396 [TBL] [Abstract][Full Text] [Related]
15. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products]. Reiss M; Büttel IC; Schneider CK Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535 [TBL] [Abstract][Full Text] [Related]
16. A comprehensive resource on EU regulatory information for investigators in gene therapy clinical research and advanced therapy medicinal products. Cohen-Haguenauer O Hum Gene Ther; 2013 Jan; 24(1):12-8. PubMed ID: 23339285 [No Abstract] [Full Text] [Related]
17. Advanced Therapy Medicinal Products and the Changing Role of Academia. Priesner C; Hildebrandt M Transfus Med Hemother; 2022 Jun; 49(3):158-162. PubMed ID: 35813600 [TBL] [Abstract][Full Text] [Related]
18. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211 [TBL] [Abstract][Full Text] [Related]
19. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving? Boráň T; Menezes-Ferreira M; Reischl I; Celis P; Ferry N; Gänsbacher B; Krafft H; Lipucci di Paola M; Sladowski D; Salmikangas P Hum Gene Ther Clin Dev; 2017 Sep; 28(3):126-135. PubMed ID: 28510497 [TBL] [Abstract][Full Text] [Related]
20. Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand. Boonprasirt P; Nimvorapun S; Sawangjang C; Poonpolsub S; Yoongthong W; Dunkum P Adv Exp Med Biol; 2023; 1430():221-233. PubMed ID: 37526851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]